Almirall (ALM.MC)

Executive Summary

Almirall is a global pharmaceutical company headquartered in Barcelona, Spain, with a core strategic focus on medical dermatology and skin health. Founded in 1943, the company has established a strong commercial presence in Europe and the United States with approved products such as tildrakizumab (Ilumetri) for plaque psoriasis and a portfolio of topical therapies for acne and other dermatological conditions. With a market valuation of approximately $2.7 billion and a track record of 9 FDA approvals, Almirall benefits from its specialized focus and direct commercial operations in key markets. The company's pipeline includes several mid-to-late-stage assets, notably LAD603 for alopecia areata, which is currently in a Phase 2 trial (NCT07311564) with recruiting status and expected completion in November 2027. While Almirall's commercial portfolio provides a stable revenue base, its near-term growth prospects depend on advancing pipeline candidates and expanding label indications for existing products. The company's conviction score of 70 reflects its solid market position and pipeline progress, tempered by limited near-term catalysts and competitive pressures in dermatology.

Upcoming Catalysts (preview)

• Q4 2026LAD603 Phase 2 data readout for alopecia areata40% success
• Q3 2026Potential EU approval decision for sarecycline (acne vulgaris)60% success
• TBDIlumetri (tildrakizumab) label expansion for pediatric psoriasis50% success